BIOMAT Database Logo BIOMAT Database Logo

CD31 expression in benign, borderline, and malignant epithelial ovarian tumors: an immunohistochemical and serological analysis. 1998

E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
Service de Gynécologie-Obstétrique, Hôpital Bichat, Université Paris, 7 Denis Diderot, Paris, 75018, France.

OBJECTIVE To evaluate (a) the expression of CD31 in benign, borderline, and maligant ovarian tumors; (b) the correlation between CD31 expression and the clinicopathological parameters; and (c) the diagnostic interest of serological soluble CD31 (sCD31) in patients with ovarian tumors. METHODS The intratumoral microvessel density was evaluated by an immunohistochemical technique with the monoclonal antibody JC70 against CD31 at two dilutions in 20 benign, 20 borderline, and 20 malignant tumors of the ovary. Serological determinations of sCD31 with ELISA technique was performed in 35 patients with ovarian tumors (24 benign, 5 borderline, and 6 malignant tumors). RESULTS The expression of CD31 was higher in ovarian carcinomas than in borderline and benign tumors (P < 0.001) irrespective of the dilutions of the antibody used. In ovarian carcinomas, a correlation was observed between CD31 expression and the stage of the disease, the histologic type, the degree of histological differentiation, and the survival of the patients. In borderline tumors, no correlation was noted between CD31 expression and the clinicopathologic parameters. No difference in serological levels of sCD31 was noted according to histologic types. CONCLUSIONS CD31 immunostaining may have a prognostic relevance in ovarian carcinoma but seems to be of limited value in borderline tumors. Serological levels of sCD31 have no diagnostic interest in ovarian tumors.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009375 Neoplasms, Glandular and Epithelial Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue. Epithelial Cell Neoplasms,Glandular Cell Neoplasms,Epithelial Neoplasms,Glandular Neoplasms,Glandular and Epithelial Neoplasms,Neoplasms, Epithelial,Neoplasms, Glandular,Neoplasms, Glandular Epithelial,Cell Neoplasm, Epithelial,Cell Neoplasm, Glandular,Cell Neoplasms, Epithelial,Epithelial Cell Neoplasm,Epithelial Neoplasm,Epithelial Neoplasm, Glandular,Glandular Cell Neoplasm,Glandular Epithelial Neoplasm,Glandular Epithelial Neoplasms,Glandular Neoplasm,Neoplasm, Epithelial,Neoplasm, Epithelial Cell,Neoplasm, Glandular,Neoplasm, Glandular Cell,Neoplasm, Glandular Epithelial
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D019408 Platelet Endothelial Cell Adhesion Molecule-1 A cell adhesion molecule, composed of a series of Ig-like domains, and expressed on virtually all MONOCYTES; PLATELETS; and GRANULOCYTES. PECAM-1 is highly expressed on endothelial cells and concentrated at the junctions between them. It is essential for TRANSENDOTHELIAL MIGRATION of leukocytes and removal of apoptotic cells by PHAGOCYTES. Antigens, CD31,CD31 Antigens,PECAM-1,CD31 Antigen,Antigen, CD31,Platelet Endothelial Cell Adhesion Molecule 1

Related Publications

E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
April 2006, Histology and histopathology,
E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
October 2016, Journal of ovarian research,
E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
Discrimination between benign, borderline, and malignant epithelial ovarian tumors using tumor markers: an immunohistochemical study.
January 1983, Cancer detection and prevention,
E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
Differentiation of Borderline Epithelial Ovarian Tumors from Benign and Malignant Epithelial Ovarian Tumors by MRI Scoring
January 2024, Current medical imaging,
E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
u-PA expression in benign, borderline and malignant ovarian tumors.
January 2002, Anticancer research,
E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
Comparative cytogenetic studies of benign, borderline, and malignant epithelial ovarian tumors.
December 1996, The journal of obstetrics and gynaecology research,
E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline and malignant tumors.
November 1997, International journal of cancer,
E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors.
January 2002, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
Serological and immunohistochemical biomarkers for discrimination between benign and malignant ovarian tumors.
January 2019, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie,
E Darai, and A F Bringuier, and F Walker-Combrouze, and A Fauconnier, and A Couvelard, and G Feldmann, and P Madelenat, and J Y Scoazec
Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors.
March 1999, International journal of cancer,
Copied contents to your clipboard!